Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2025-08-05 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients and the total number of shares granted due to employee departures. This type of disclosure regarding stock option plans and capital structure changes falls under the category of 'Regulatory Filings' (RNS) as it is a specific corporate disclosure required by the Korea Exchange/Financial Supervisory Service that does not fit into more specific categories like 'Director's Dealing' (which is for individual trades) or 'Share Issue' (which is for capital changes).
2025-08-05 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고' (Amendment Report). It details changes to the number of stock options granted to employees and directors due to resignations. This type of filing relates to capital structure and equity-based compensation, which falls under the 'Share Issue/Capital Change' category in the provided schema.
2025-08-05 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which directly impacts the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2025-07-29 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory disclosure regarding the acquisition of convertible bonds before maturity (specifically a call option exercise). This relates to the company's capital structure and financing activities. According to the provided definitions, updates on financing activities and capital structure changes fall under the 'CAP' (Capital/Financing Update) category.
2025-06-23 Korean
주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the 'Decision to Sell Own Convertible Bonds' (자기 전환사채 매도 결정). This document details the specific terms of a financial transaction involving the sale of previously acquired convertible bonds to third-party investors (Brookdale funds). Since this relates to financing activities and capital structure changes, it falls under the 'Capital/Financing Update' category.
2025-06-23 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it does not fit into other specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2025-06-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.